---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-010775"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T08:25:09.639887+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath Q4 revenue $15.1M, positive adjusted EBITDA; FY revenue $37.2M, no debt

## Summary
- Q4 total revenue $15.1M ($13.7M HEPZATO US, $1.4M CHEMOSAT Europe); FY total $37.2M.
- Q4 net loss narrowed to $3.4M from $11.1M; FY net loss $26.4M from $47.7M.
- Q4 non-GAAP adjusted EBITDA positive $4.6M; FY adjusted EBITDA loss $2.5M.
- Year-end cash & investments $53.2M; no debt; warrant exercises generated $41.3M in 2024.
- 16 active US centers; FDA clearance for Phase 2 HEPZATO trial in mCRC; NCCN update recommends HEPZATO for mUM.

## SEC filing metadata
- accession: 0001628280-25-010775
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/0001628280-25-010775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/dcth-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-010775
- JSON: https://secwatch.observer/filing/0001628280-25-010775.json
- Plain text: https://secwatch.observer/filing/0001628280-25-010775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.